PULMATRIX Aktie

Pulmatrix, Inc. is a clinical stage biotechnology company, which is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. It designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Edwards, Mark Gabrielson, Alexander Klibanov, and Robert Langer in 2013 and is headquartered in Lexington, MA.